(Z)-4-(3-AMINO-4,4,4-TRIFLUOROBUT-2-ENOYL)BENZONITRILE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SSLBNNYGLVCOJK-YHYXMXQVSA-N
Smiles	N\C(=C/C(=O)c1ccc(cc1)C#N)\C(F)(F)F
InChI	InChI=1S/C11H7F3N2O/c12-11(13,14)10(16)5-9(17)8-3-1-7(6-15)2-4-8/h1-5H,16H2/b10-5-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C11H7F3N2O
Molecular Weight	240.18
AlogP	1.81
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	66.88
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	17.0

Assay Description	Organism	Bioactivity
Phytotoxicity against Solanum lycopersicum (tomato) leaves	Solanum lycopersicum	None
Phytotoxicity against Medicago sativa (alfalfa) assessed as seed germination	Medicago sativa	None
Antifungal activity against Pythium aphanidermatum assessed as radial growth inhibition at 10 to 100 uM	Pythium aphanidermatum	None
Antifungal activity against Rhizoctonia solani assessed as radial growth inhibition at 10 to 100 uM	Rhizoctonia solani	None
Antifungal activity against Alternaria alternata assessed as radial growth inhibition at 100 uM	Alternaria alternata	50.0 %
Antifungal activity against Botryotinia fuckeliana isolate Bcl16 assessed as radial growth inhibition at 10 to 100 uM	Botryotinia fuckeliana	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2251703
PubChem	44247922
SureChEMBL	SCHEMBL3422391

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).